DCF Advisers LLC Reduces Stake in AnaptysBio, Inc. $ANAB

DCF Advisers LLC reduced its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 26.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 35,250 shares of the biotechnology company’s stock after selling 12,750 shares during the period. DCF Advisers LLC’s holdings in AnaptysBio were worth $1,709,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ANAB. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. increased its stake in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares in the last quarter. Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Daniel Faga sold 17,679 shares of AnaptysBio stock in a transaction on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the transaction, the chief executive officer owned 495,965 shares in the company, valued at approximately $30,556,403.65. This trade represents a 3.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John P. Schmid sold 20,645 shares of AnaptysBio stock in a transaction on Monday, March 30th. The shares were sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares in the company, valued at $1,774,310.42. The trade was a 39.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 33.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ANAB has been the subject of several research analyst reports. HC Wainwright initiated coverage on AnaptysBio in a research note on Wednesday. They issued a “buy” rating and a $95.00 price objective for the company. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Truist Financial raised AnaptysBio to a “hold” rating in a research report on Wednesday, March 25th. Stifel Nicolaus raised their price target on AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Barclays raised their price target on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.82.

AnaptysBio Stock Up 0.9%

Shares of NASDAQ:ANAB opened at $52.10 on Thursday. The company has a market cap of $1.52 billion, a P/E ratio of -48.24 and a beta of 0.72. AnaptysBio, Inc. has a 52 week low of $11.40 and a 52 week high of $72.36. The business has a fifty day simple moving average of $60.38 and a 200-day simple moving average of $54.30.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. Sell-side analysts expect that AnaptysBio, Inc. will post -0.93 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a share buyback plan on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.